Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer

Folefac Aminkeng^{1

2}, Colin J D Ross³, Shahrad R Rassekh^{2

4}, Michael J Rieder⁵, Amit P Bhavsar³, Shubhayan Sanatani², Daniel Bernstein⁶, Michael R Hayden^{1

2

7}, Ursula Amstutz⁸, Bruce C Carleton^{2

9}

Affiliations

¹ Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
² BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
³ Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
⁴ Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
⁵ Department of Pediatrics, University of Western Ontario, London, Ontario, Canada.
⁶ Department of Pediatrics, Division of Cardiology, Stanford University, Stanford, California, USA.
⁷ Teva Pharmaceutical Industries, Petach Tikva, Israel.
⁸ University Institute of Clinical Chemistry, Inselspital Bern University Hospital and University of Bern, Switzerland.
⁹ Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.

PMID: 28317142
PMCID: PMC5401971
DOI: 10.1111/bcp.13218

Comment

Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer

Folefac Aminkeng et al. Br J Clin Pharmacol. 2017 May.

. 2017 May;83(5):1143-1145.

doi: 10.1111/bcp.13218. Epub 2017 Mar 19.

Authors

Affiliations

¹ Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
² BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
³ Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
⁴ Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
⁵ Department of Pediatrics, University of Western Ontario, London, Ontario, Canada.
⁶ Department of Pediatrics, Division of Cardiology, Stanford University, Stanford, California, USA.
⁷ Teva Pharmaceutical Industries, Petach Tikva, Israel.
⁸ University Institute of Clinical Chemistry, Inselspital Bern University Hospital and University of Bern, Switzerland.
⁹ Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.

PMID: 28317142
PMCID: PMC5401971
DOI: 10.1111/bcp.13218

No abstract available

Keywords: anthracycline; anthracycline-induced cardiotoxicity; cancer; chemotherapy; clinical practice guidelines; congestive heart failure; pharmacogenomic screening.

PubMed Disclaimer

Comment on

Genetic determinants of anthracycline cardiotoxicity - ready for the clinic?
Craig LA, Ekert PG, Conyers R, Elliott DA. Craig LA, et al. Br J Clin Pharmacol. 2017 May;83(5):1141-1142. doi: 10.1111/bcp.13195. Epub 2017 Jan 24. Br J Clin Pharmacol. 2017. PMID: 28120432 Free PMC article. No abstract available.

References

1. Craig LA, Ekert PG, Conyers R, Elliott DA. Genetic determinants of Anthracycline cardiotoxicity – ready for the clinic? Br J Clin Pharmacol 2017; 83: 1141–1142. - PMC - PubMed
1. Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, et al. Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity. Br J Clin Pharmacol 2016; 82: 683–695. - PMC - PubMed
1. Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, et al. A coding variant in RARG confers susceptibility to anthracycline‐induced cardiotoxicity in childhood cancer. Nat Genet 2015; 47: 1079–1084. - PMC - PubMed
1. Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline‐induced cardiotoxicity in children. Pediatr Blood Cancer 2013; 60: 1375–1381. - PubMed
1. Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dube MP, Al‐Saloos H, et al. Pharmacogenomic prediction of anthracycline‐induced cardiotoxicity in children. J Clin Oncol 2012; 30: 1422–1428. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer

Affiliations

Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer

Authors

Affiliations

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Other Literature Sources